SCHEDULE 13G/A: Vanguard Group Amends Stake in Gossamer Bio, Reports 4.42% Passive Ownership

The Vanguard Group has filed an Amendment No. 5 to its Schedule 13G, disclosing a 4.42% beneficial ownership stake in Gossamer Bio Inc. as of December 31, 2024.

Summary

• The Vanguard Group reported beneficial ownership of 10,034,149 shares of Gossamer Bio Inc. common stock.
• This ownership represents 4.42% of the total class of securities.
• Vanguard holds sole dispositive power over 9,965,539 shares and shared dispositive power over 68,610 shares.
• The filing indicates that The Vanguard Group holds no sole or shared voting power over these shares.
• This document is an Amendment No. 5 to a Schedule 13G, signifying an update to previous ownership disclosures where Vanguard's stake was likely above the 5% threshold.

Sentiment

Score: 5

Explanation: This is a neutral regulatory filing disclosing passive ownership. While a large institutional holding can be seen as positive, the reduction below 5% (implied by the amendment) could be viewed neutrally to slightly negatively by some, but it's primarily a factual update without operational implications for the company.

Positives

• The Vanguard Group, a prominent institutional investor, continues to hold a substantial stake in Gossamer Bio Inc., which may signal ongoing institutional interest in the company.

Negatives

• The reported beneficial ownership of 4.42% is below the 5% threshold, indicating a reduction in The Vanguard Group's stake from previous filings that initially triggered the Schedule 13G requirement.

Future Outlook

This Schedule 13G filing is a disclosure of current ownership and does not contain forward-looking statements or guidance regarding Gossamer Bio Inc.'s future operations or financial performance.

Management Comments

• This filing is from The Vanguard Group, an institutional investor, and does not contain direct management comments from Gossamer Bio Inc. The Vanguard Group certified that the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Industry Context

This filing reflects a routine disclosure by a large asset manager, The Vanguard Group, regarding its passive investment in a biotechnology company, Gossamer Bio Inc. Such institutional holdings are common across various industries and indicate a fund's portfolio allocation rather than specific industry trends, though a reduction in stake by a major holder could be noted by market participants.

Comparison to Industry Standards

• This document is a standard Schedule 13G filing, which is a regulatory disclosure of passive ownership. It does not contain operational or financial results from Gossamer Bio Inc. that would allow for a comparison to industry-specific benchmarks or competitor performance. The filing itself adheres to SEC reporting standards for institutional ownership disclosures.

Stakeholder Impact

• Shareholders: Provides transparency on a significant institutional investor's stake, indicating a reduction in The Vanguard Group's reported beneficial ownership below the 5% threshold.

Key Dates

Keywords

Gossamer Bio Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, GBIO